Jul 24, 2008 - EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it is scheduled to make two presentations at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease in Chicago...
...In May 2008, EPIX announced the initiation of a Phase 2b proof-of-concept program for PRX-03140 that consists of two clinical trials - a six-month trial evaluating PRX-03140 in combination with donepezil and a three-month trial studying PRX-03140 as monotherapy. PRX-03140 is part of EPIX's strategic collaboration with GlaxoSmithKline, which is conducted through GSK's Center of Excellence for External Drug Discovery (CEEDD)... EPIX Pharmaceuticals' Press Release -
